Pharma marketing strategy is a key part of every consulting project we do, whether it be a landscape report, thought leader market research or identifying target opportunities for oncology and hematology new products. We are constantly on the look out for fast-to-market strategies in market segments with high unmet medical need where emerging science and […]
Chimeric Antigen Receptor T cell immunotherapy (known as CAR-T or more colloquially as CART) has been in the news recently. Novartis/UPenn announced they received Breakthrough Therapy Designation (BTD) from the US Food & Drug Administration (FDA) for their CTL019 product in relapsed/refractory acute lymphocytic leukemia (ALL). Dr Stephen Grupp from The Children’s Hospital of Philadelphia […]
Immuno-oncology was one of the hot topics in cancer drug development at ASCO 2014. Readers may recall my ASCO 2013 preview video that highlighted the significance of data for immune checkpoint inhibitors – this was when anti PD-1, PD-L1 compounds were generally not on many people’s radar. One thing we work hard at is picking […]
The annual pilgrimage for cancer drug development professionals to ASCO (the annual meeting of the American Society of Clinical Oncology) in Chicago is over, and now we have to digest the tsunami of data such meetings create. The challenge with conferences such as these is not obtaining access to data – most of it is […]
Science is driving combination therapies to overcome resistance and increase effectiveness. That is the future oncology landscape that anyone bringing new products to market needs to be aware of.
A modern David versus Goliath story in cancer drug development is unfolding as Clovis Oncology race to market against AstraZeneca; both companies have drugs in early clinical development that appear effective against T790M mutated lung cancer, for which there is currently no approved treatment.
One of the hot topic of conversation amongst the VCs at the JP Morgan Healthcare conference in San Francisco this past week was the field of immuno-oncology. We have already seen significant excitement in anti-PD1/PD-L1 drugs and their early promise in melanoma, renal and lung cancers. Taking a more strategic view, however, the question is how will immuno-oncology change the treatment landscape on a broader scale?
In response to numerous client requests, one of the services we now offer is 1:1 executive coaching on Oncology New Product Development. The aim of this program is to facilitate a greater understanding of emerging cancer targets through a series of custom case studies and 1:1 coaching sessions.
For those on the cancer conference circuit, 2014 is the year of the west coast swing, with 3 major meetings in San Francisco and two in San Diego. Here’s our calendar of key cancer meetings that we plan to attend in person or write about on Biotech Strategy Blog and Pharma Strategy Blog.
AZD9291 is a promising new lung cancer drug active against T790M mutation in patients refractory to prior EGFR therapy. Updated early phase 1 data for the AURA trial was presented at the World Conference on Lung Cancer.